Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:44 AM
Ignite Modification Date:
2025-12-25 @ 12:44 AM
NCT ID:
NCT05770167
Eligibility Criteria:
Inclusion Criteria:
* Age \>18 years
* stable clinical conditions
* Diagnosis of heart failure according to European guidelines (ESC) with EF≤40%
* New York Heart Association Class (NYHA) II-III, despite optimised treatment for heart failure, candidates for treatment with Dapagliflozin according to current guidelines
* Ability to perform cardiopulmonary testing (CPET)
* Patients who have signed written informed consent
Exclusion Criteria:
* Contraindication for Dapaglilozin prescription
* Moderate-severe obstructive pulmonary disease (COPD)
* Estimated glomerular filtrate (eGFR) \<30 mL/min/1.73m2 according to MDRD criteria
* Inability or contraindication to perform a CPET
* Taking an investigational drug within 30 days prior to administration of Dapagliflozin
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT05770167
Study Brief:
Protocol Section:
NCT05770167